Brief: Aim Immunotech Announces Open Enrollment For Phase 1B/2 Study Evaluating Ampligen (Rintatolimod) In Combination With Astrazeneca’S Imfinzi (Durvalumab) For The Treatment Of Pancreatic Cancer
10/01/2024 13:46
Jan 10 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES OPEN ENROLLMENT FOR PHASE 1B/2
STUDY
EVALUATING AMPLIGEN® (RINTATOLIMOD) IN COMBINATION WITH
ASTRAZENECA’S IMFINZI® (DURVALUMAB) FOR THE TREATMENT OF
PANCREATIC CANCER
* AIM IMMUNOTECH INC - FIRST ENROLLMENT AND FIRST SUBJECT
DOSING
EXPECTED SOON AT ERASMUS MEDICAL CENTER IN ROTTERDAM,
NETHERLANDS
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential